A Study of NG-641 and Pembrolizumab in Squamous Cell Carcinoma of the Head and Neck
Last updated on July 2021Recruitment
- Recruitment Status
- Not yet recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Squamous Cell Carcinoma of the Head and Neck
- Type
- Interventional
- Phase
- Phase 1
- Design
- Allocation: Non-RandomizedIntervention Model: Sequential AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
Part A (NG-641 monotherapy): Up to 18 patients will be dosed with intravenous NG-641. Patients will then proceed to planned surgical resection. Part B (NG-641 and pembrolizumab): Up to 30 patients will be dosed with intravenous NG-641 before receiving a single dose of pembrolizumab. Patients will th...
Part A (NG-641 monotherapy): Up to 18 patients will be dosed with intravenous NG-641. Patients will then proceed to planned surgical resection. Part B (NG-641 and pembrolizumab): Up to 30 patients will be dosed with intravenous NG-641 before receiving a single dose of pembrolizumab. Patients will then proceed to planned surgical resection.
Tracking Information
- NCT #
- NCT04830592
- Collaborators
- Not Provided
- Investigators
- Principal Investigator: Christian Ottensmeier, Prof. The Clatterbridge Cancer Centre
Get Well Soon